Age Related Macular Degeneration (ARMD) Terminated Phase 1 / 2 Trials for Ranibizumab (DB01270)

Also known as: Age Related Macular Degeneration

IndicationStatusPhase
DBCOND0055169 (Age Related Macular Degeneration (ARMD))Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01025232A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)Treatment